Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- None.
- None.
The Options have a grant date of October 2, 2023 and an exercise price of
The Option awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.
The foregoing equity awards were granted as an inducement material to the employees entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individual's entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil recently completed its Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and is in a Phase 2 proof-of-concept trial for the treatment of patients with AFib-RVR. Milestone Pharmaceuticals operates in
Contact:
Kim Fox, Vice President, Communications
kfox@milestonepharma.com
704-803-9295
View original content:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301948977.html
SOURCE Milestone Pharmaceuticals, Inc.
FAQ
What did Milestone Pharmaceuticals announce?
How many options were granted?
What is the exercise price of the options?
When will the shares subject to the options vest?